Neuren Pharmaceuticals Limited (ASX: NEU) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Neuren Pharmaceuticals Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Neuren Pharmaceuticals Limited (ASX: NEU)
Latest News
Healthcare Shares
This ASX 300 healthcare stock is up 48% in 3 days. Broker says buy
Share Gainers
Why Kingsgate, Neuren, Newcrest, and Pushpay shares are rising today
Share Gainers
Why Neuren, Northern Star, Race Oncology, and Westgold shares are storming higher
Healthcare Shares
Guess which ASX All Ords stock is rocketing 27% on a new FDA approval
52-Week Highs
4 ASX All Ordinaries shares hitting new 52-week highs today
Opinions
2 little-known ASX 300 shares with big potential: expert
Share Gainers
3 ASX All Ordinaries shares defying today's downturn to rocket higher
52-Week Highs
3 ASX All Ordinaries shares hitting multi-year highs on Tuesday
Share Gainers
3 ASX All Ordinaries shares smashing multi-year highs today
Share Gainers
Why Leo Lithium, Myer, Neuren, and Peter Warren shares are rising today
Share Gainers
Why Allkem, MA Financial, Neuren, and Vulcan Energy shares are pushing higher
Earnings Results
Here are 3 ASX healthcare share results you might have missed
Frequently Asked Questions
-
No, Neuren Pharmaceuticals does not pay dividends at this time.
-
Neuren Pharmaceuticals Limited (ASX: NEU) listed on the ASX on 3 February 2005.
NEU ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited (ASX: NEU) is a biopharmaceutical company specialising in developing new therapies for neurodevelopmental disorders that emerge in early childhood and are characterised by impaired connections and signalling between brain cells.
In March 2023, the US Food and Drug Administration approved DAYBUE™ (trofinetide) for the treatment of Rett syndrome in adults and children two years and older. Neuren's US partner Acadia Pharmaceuticals (NASDAQ: ACAD) holds a worldwide exclusive licence from Neuren for trofinetide. At this time, DAYBUE is the first and only drug approved for the treatment of Rett syndrome. Trofinetide has also demonstrated clinical benefit in a Phase 2 trial in treating Fragile X syndrome.
Neuren's second product NNZ-2591 is currently in Phase 2 clinical trials for the treatment of Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome, and Prader-Willi syndrome. The drug candidate has shown positive effects in mouse models of each syndrome and was successful in a Phase 1 clinical trial. The number of patients across these four disorders is estimated as five times the number of Rett syndrome patients. There are currently no drugs approved for these conditions, apart from growth hormone to treat some aspects of Prader-Willi.
Acadia Pharmaceuticals also holds a worldwide exclusive licence to develop and commercialise NNZ-2591 for Rett syndrome and Fragile X syndrome. Neuren retains worldwide rights to NNZ-2591 in all other indications.
